|8th February 2021||Jeffrey F Odonnell||42,762||Open or private sale||$5.12||$219,099.66|
|5th February 2021||Jeffrey F Odonnell||62,238||Open or private sale||$5.00||$311,270.91|
|6th January 2021||Jerome B Zeldis||1,650||Grant/award etc.||$0.00|
|4th January 2021||Steve Chaussy||150,000||Grant/award etc.||$0.00|
|4th January 2021||Kenneth L Londoner||300,000||Grant/award etc.||$0.00|
|1st December 2020||Steve Chaussy||2,000||Open or private purchase||$4.35||$8,699.00|
|30th November 2020||Kenneth L Londoner||2,000||Open or private purchase||$4.65||$9,300.00|
|24th November 2020||Kenneth L Londoner||1,000||Open or private purchase||$4.33||$4,330.00|
|23rd November 2020||Kenneth L Londoner||1,000||Open or private purchase||$4.51||$4,510.00|
|23rd November 2020||Kenneth L Londoner||1,000||Open or private purchase||$4.39||$4,390.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
BioSig Technologies, Inc. is a medical technology company developing a biomedical signal processing platform. The company is preparing to commercialize its PURE EP™ System. The technology has been developed to address an unmet need in a large and growing market.